{"pmid":32386448,"title":"Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman.","text":["Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman.","The antimalarials, Chloroquine and Hydroxychloroquine (HCQ), and the antivirals Lopinavir/Ritonavir have been recently recorded as having anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) effects.(1) In particular, regarding Italy, one of the countries most affected by the pandemic, the Italian Society of Infectious and Tropical disease (Lombardy section) has recommended the use of HCQ for treatment of coronavirus disease 2019 (COVID-19).","J Eur Acad Dermatol Venereol","Robustelli Test, E","Vezzoli, P","Carugno, A","Raponi, F","Gianatti, A","Rongioletti, F","Sena, P","32386448"],"abstract":["The antimalarials, Chloroquine and Hydroxychloroquine (HCQ), and the antivirals Lopinavir/Ritonavir have been recently recorded as having anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) effects.(1) In particular, regarding Italy, one of the countries most affected by the pandemic, the Italian Society of Infectious and Tropical disease (Lombardy section) has recommended the use of HCQ for treatment of coronavirus disease 2019 (COVID-19)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Robustelli Test, E","Vezzoli, P","Carugno, A","Raponi, F","Gianatti, A","Rongioletti, F","Sena, P"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32386448","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jdv.16613","keywords":["acute generalized exanthematous pustulosis (agep)","covid-19","drug reaction","hydroxychloroquine (hcq)","skin","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Case Report"],"weight":1,"_version_":1666340101965217792,"score":9.490897,"similar":[{"pmid":32338155,"title":"Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.","text":["Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.","The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic.","Emerg Microbes Infect","Sun, Xiaoxuan","Ni, Yicheng","Zhang, Miaojia","32338155"],"abstract":["The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic."],"journal":"Emerg Microbes Infect","authors":["Sun, Xiaoxuan","Ni, Yicheng","Zhang, Miaojia"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338155","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1080/22221751.2020.1760145","keywords":["covid-19","chloroquine (cq)","sars-cov-2","hydroxychloroquine (hcq)","therapy"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138494190223360,"score":199.6858},{"pmid":32445583,"title":"Erythema multiforme-like lesions in children and COVID-19.","text":["Erythema multiforme-like lesions in children and COVID-19.","During examination of cases of chilblains in children and adolescents, we identified four patients who also showed skin lesions similar to erythema multiforme (EM). They had no other known triggers for EM. One of them had a positive PCR for SARS-CoV-2, while the other 3 were negative. Skin biopsies from two patients showed features not typical of EM, such as deep perivascular and perieccrine infiltrate and absence of necrosis of keratinocytes. Immunohistochemistry for SARS-CoV/SARS-CoV-2 spike protein showed granular positivity in endothelial cells and epithelial cells of eccrine glands in both biopsies. All patients had an excellent outcome, and had minimal or no systemic symptoms. The coincidence of EM, a condition commonly related to viruses, and chilblains in the setting of COVID-19, as well as the positivity for SARS-CoV/SARS-CoV-2 spike protein by immunohistochemistry strongly suggest a link between EM-like lesions and SARS-CoV-2.","Pediatr Dermatol","Torrelo, Antonio","Andina, David","Santonja, Carlos","Noguera-Morel, Lucero","Bascuas-Arribas, Marta","Gaitero-Tristan, Jara","Alonso-Cadenas, Jose Antonio","Escalada-Pellitero, Silvia","Hernandez-Martin, Angela","de la Torre-Espi, Mercedes","Colmenero, Isabel","32445583"],"abstract":["During examination of cases of chilblains in children and adolescents, we identified four patients who also showed skin lesions similar to erythema multiforme (EM). They had no other known triggers for EM. One of them had a positive PCR for SARS-CoV-2, while the other 3 were negative. Skin biopsies from two patients showed features not typical of EM, such as deep perivascular and perieccrine infiltrate and absence of necrosis of keratinocytes. Immunohistochemistry for SARS-CoV/SARS-CoV-2 spike protein showed granular positivity in endothelial cells and epithelial cells of eccrine glands in both biopsies. All patients had an excellent outcome, and had minimal or no systemic symptoms. The coincidence of EM, a condition commonly related to viruses, and chilblains in the setting of COVID-19, as well as the positivity for SARS-CoV/SARS-CoV-2 spike protein by immunohistochemistry strongly suggest a link between EM-like lesions and SARS-CoV-2."],"journal":"Pediatr Dermatol","authors":["Torrelo, Antonio","Andina, David","Santonja, Carlos","Noguera-Morel, Lucero","Bascuas-Arribas, Marta","Gaitero-Tristan, Jara","Alonso-Cadenas, Jose Antonio","Escalada-Pellitero, Silvia","Hernandez-Martin, Angela","de la Torre-Espi, Mercedes","Colmenero, Isabel"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445583","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/pde.14246","keywords":["covid-19","sars-cov-2","chilblain","erythema multiforme","pernio","skin"],"topics":["Case Report"],"weight":1,"_version_":1667600475817508864,"score":175.10724},{"pmid":32455478,"title":"A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an issue.","text":["A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an issue.","We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID-19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.","J Eur Acad Dermatol Venereol","Torres-Navarro, Ignacio","Abril-Perez, Carlos","Roca-Gines, Juncal","Sanchez-Arraez, Javier","Botella-Estrada, Rafael","32455478"],"abstract":["We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID-19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered."],"journal":"J Eur Acad Dermatol Venereol","authors":["Torres-Navarro, Ignacio","Abril-Perez, Carlos","Roca-Gines, Juncal","Sanchez-Arraez, Javier","Botella-Estrada, Rafael"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32455478","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jdv.16664","keywords":["acute generalized exanthematous pustulosis (agep)","covid-19","sars-cov-2","severe cutaneous adverse reactions (scars)"],"e_drugs":["cefditoren"],"topics":["Treatment"],"weight":1,"_version_":1667983494515523585,"score":157.66412},{"pmid":32323646,"title":"Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings.","text":["Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings.","The novel severe acute respiratory syndrome-coronavirus-2 pandemic has spread to Africa, where nearly all countries have reported laboratory-confirmed cases of novel coronavirus disease (COVID-19). Although there are ongoing clinical trials of repurposed and investigational antiviral and immune-based therapies, there are as yet no scientifically proven, clinically effective pharmacological treatments for COVID-19. Among the repurposed drugs, the commonly used antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) have become the focus of global scientific, media, and political attention despite a lack of randomized clinical trials supporting their efficacy. Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria. Hydroxychloroquine is mainly used as a therapy for autoimmune diseases. However, the efficacy and safety of CQ/HCQ for the treatment of COVID-19 remains to be defined. Indiscriminate promotion and widespread use of CQ/HCQ have led to extensive shortages, self-treatment, and fatal overdoses. Shortages and increased market prices leave all countries vulnerable to substandard and falsified medical products, and safety issues are especially concerning for Africa because of its healthcare system limitations. Much needed in Africa is a cross-continental collaborative network for coordinated production, distribution, and post-marketing surveillance aligned to low-cost distribution of any approved COVID-19 drug; this would ideally be piggybacked on existing global aid efforts. Meanwhile, African countries should strongly consider implementing prescription monitoring schemes to ensure that any off-label CQ/HCQ use is appropriate and beneficial during this pandemic.","Am J Trop Med Hyg","Abena, Pascale M","Decloedt, Eric H","Bottieau, Emmanuel","Suleman, Fatima","Adejumo, Prisca","Sam-Agudu, Nadia A","Muyembe TamFum, Jean-Jacques","Seydi, Moussa","Eholie, Serge P","Mills, Edward J","Kallay, Oscar","Zumla, Alimuddin","Nachega, Jean B","32323646"],"abstract":["The novel severe acute respiratory syndrome-coronavirus-2 pandemic has spread to Africa, where nearly all countries have reported laboratory-confirmed cases of novel coronavirus disease (COVID-19). Although there are ongoing clinical trials of repurposed and investigational antiviral and immune-based therapies, there are as yet no scientifically proven, clinically effective pharmacological treatments for COVID-19. Among the repurposed drugs, the commonly used antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) have become the focus of global scientific, media, and political attention despite a lack of randomized clinical trials supporting their efficacy. Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria. Hydroxychloroquine is mainly used as a therapy for autoimmune diseases. However, the efficacy and safety of CQ/HCQ for the treatment of COVID-19 remains to be defined. Indiscriminate promotion and widespread use of CQ/HCQ have led to extensive shortages, self-treatment, and fatal overdoses. Shortages and increased market prices leave all countries vulnerable to substandard and falsified medical products, and safety issues are especially concerning for Africa because of its healthcare system limitations. Much needed in Africa is a cross-continental collaborative network for coordinated production, distribution, and post-marketing surveillance aligned to low-cost distribution of any approved COVID-19 drug; this would ideally be piggybacked on existing global aid efforts. Meanwhile, African countries should strongly consider implementing prescription monitoring schemes to ensure that any off-label CQ/HCQ use is appropriate and beneficial during this pandemic."],"journal":"Am J Trop Med Hyg","authors":["Abena, Pascale M","Decloedt, Eric H","Bottieau, Emmanuel","Suleman, Fatima","Adejumo, Prisca","Sam-Agudu, Nadia A","Muyembe TamFum, Jean-Jacques","Seydi, Moussa","Eholie, Serge P","Mills, Edward J","Kallay, Oscar","Zumla, Alimuddin","Nachega, Jean B"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323646","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.4269/ajtmh.20-0290","e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138493824270336,"score":146.56253},{"pmid":32496926,"title":"Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.","text":["Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.","Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. Antiviral therapy is the most important treatment for COVID-19. Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.","Postgrad Med","Sun, JingKang","Chen, YuTing","Fan, XiuDe","Wang, XiaoYun","Han, QunYing","Liu, ZhengWen","32496926"],"abstract":["Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. Antiviral therapy is the most important treatment for COVID-19. Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies."],"journal":"Postgrad Med","authors":["Sun, JingKang","Chen, YuTing","Fan, XiuDe","Wang, XiaoYun","Han, QunYing","Liu, ZhengWen"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32496926","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/00325481.2020.1778982","keywords":["sars-cov-2","antiviral","chloroquine","coronavirus","hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1668712823972167680,"score":137.83278}]}